SCHEMBL14829969

SCHEMBL14829969

O=C(O)NC[C@@](O)(c1ccc(Cl)cc1)c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
HTT P42858 5/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
XBP1 P17861 1/20 0.48
MAPK1 P28482 1/20 0.48
SCN5A Q14524 3/20 0.44
SCN9A Q15858 3/20 0.44
CYP19A1 P11511 1/20 0.43
LMNA P02545 4/20 0.42
GAA P10253 1/20 0.42
MIF P14174 1/20 0.41
POLB P06746 1/20 0.41
KIF11 P52732 2/20 0.40
CNR1 P21554 1/20 0.40
BCL2 P10415 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15975053 0.88 NPSR1 (0.56) NPSR1SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL2065478 0.79 MEN1 (0.50) NPSR1SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL8225124 0.74 EPHX2 (0.47) SMN1; SMN2MEN1KMT2ASCN5ASCN9A
SCHEMBL26930231 0.72 NPSR1 (0.43) NPSR1SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL26930210 0.71 NPSR1 (0.42) NPSR1SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL30606439 0.70 KIF11 (0.49) NPSR1SMN1; SMN2HTTL3MBTL1MAPK1
SCHEMBL11618396 0.70 KIF11 (0.49) NPSR1SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL10862316 0.68 NPSR1 (0.54) NPSR1SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL26930303 0.68 NPSR1 (0.51) NPSR1SMN1; SMN2HTTL3MBTL1MEN1
SCHEMBL3172531 0.68 CYP2C9 (0.47) NPSR1HTTL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760845-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2014-08-06 EP disclosed
WO-2013049250-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2013-04-04 WO disclosed